Feb 6, 2026 06:17AM
Jan 21, 2026 10:30PM
Jan 21, 2026 10:30PM
Jan 20, 2026 04:01PM
Jan 20, 2026 04:01PM
Jan 20, 2026 09:01AM
Jan 20, 2026 09:00AM BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026
Jan 12, 2026 09:01AM
Jan 12, 2026 09:00AM
Dec 8, 2025 06:42PM
Dec 4, 2025 09:01AM
Dec 4, 2025 09:00AM
Dec 4, 2025 02:13AM
Nov 18, 2025 07:02PM New data on lecanemab to be presented at CTAD conference
Nov 13, 2025 06:50PM
Nov 6, 2025 04:45PM
Oct 26, 2025 10:56PM
Sep 2, 2025 11:01PM
Aug 25, 2025 03:26AM
Aug 15, 2025 09:00AM
Aug 15, 2025 09:00AM BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
Aug 6, 2025 04:30PM
Jul 30, 2025 10:54PM
Jun 21, 2025 06:00PM
Jun 17, 2025 09:08AM
Jun 17, 2025 09:00AM
Jun 3, 2025 09:00AM
May 29, 2025 09:00AM BioAge Labs (BIOA) completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic
May 29, 2025 09:00AM
May 15, 2025 04:56AM
May 8, 2025 07:49AM
May 6, 2025 04:30PM
Apr 24, 2025 08:28AM
Apr 22, 2025 08:13AM
Apr 1, 2025 06:14AM The European Commission refers lecanemab decision to Appeal Committee
Mar 25, 2025 03:08AM
Mar 17, 2025 02:34PM
Mar 17, 2025 01:49PM
Mar 3, 2025 03:17AM
Feb 28, 2025 08:11AM
Feb 18, 2025 02:13AM
Jan 31, 2025 07:12AM Update on regulatory review of lecanemab for treatment of early Alzheimer's disease in the European Union
Jan 26, 2025 09:50PM
Jan 13, 2025 09:49PM
Dec 9, 2024 07:12AM
Dec 6, 2024 04:35PM
Dec 4, 2024 09:44PM
Nov 27, 2024 09:47PM
Nov 14, 2024 12:00PM CHMP issues positive recommendation for approval of lecanemab in the EU
Oct 31, 2024 07:43PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All